Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 286.7% in July

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 1,150,114 shares, a growth of 286.7% from the July 15th total of 297,452 shares. Based on an average daily volume of 7,664,901 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.6% of the company’s shares are sold short.

Institutional Investors Weigh In On Entera Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Superstring Capital Management LP bought a new stake in Entera Bio in the 4th quarter worth approximately $33,000. Citadel Advisors LLC raised its stake in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the period. Jane Street Group LLC lifted its holdings in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ENTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Entera Bio Stock Performance

Shares of NASDAQ:ENTX opened at $2.80 on Thursday. The firm has a market cap of $138.01 million, a price-to-earnings ratio of -8.00 and a beta of 1.38. The business has a 50-day simple moving average of $1.95 and a two-hundred day simple moving average of $1.52. Entera Bio has a fifty-two week low of $0.91 and a fifty-two week high of $4.20.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). As a group, research analysts predict that Entera Bio will post -0.34 earnings per share for the current year.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.